ABBOTT LABORATORIES

ABT

Pharmaceutical preparations

Last filing · Quarter 2 · Jun 30, 2026

40 more quarters with Pro

ABBOTT LABORATORIES back to 2009, every line as filed.

USD ($) $ in Millions, shares in Thousands	Jun 30, 2026	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Sep 30, 2022
Net sales	$ 12,593	$ 11,164	$ 11,369	$ 11,142	$ 10,358	$ 10,635	$ 10,377	$ 9,964	$ 10,143	$ 9,978	$ 9,747	$ 10,410
Cost of products sold, excluding amortization of intangible assets	5,325	4,890	5,075	4,854	4,468	4,698	4,603	4,463	4,605	4,483	4,331	4,629
Amortization of intangible assets	658	422	420	420	420	470	471	472	496	498	491	498
Cost of products sold, excluding amortization of intangible assets	-	-	-	-	-	-	-	-	-	-	-	-
Research and development	892	767	766	725	716	713	698	684	672	715	654	782
Acquired in-process and collaborations research and development	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development	-	-	-	-	-	-	-	-	-	-	-	-
Selling, general, and administrative	4,025	3,740	3,051	3,091	3,061	2,895	2,936	2,959	2,723	2,740	2,762	2,731
Total operating cost and expenses	10,900	9,819	9,312	9,090	8,665	8,776	8,708	8,578	8,496	8,436	8,238	8,640
Operating earnings	1,693	1,345	2,057	2,052	1,693	1,859	1,669	1,386	1,647	1,542	1,509	1,770
Interest expense	351	174	121	121	131	142	140	141	166	159	153	141
Interest (income)	(52)	(106)	(77)	(71)	(82)	(91)	(82)	(80)	(97)	(98)	(101)	(55)
Net foreign exchange (gain) loss	4	(13)	(17)	(11)	(7)	(11)	(6)	0	(10)	21	6	19
Net loss on extinguishment of debt	-	-	-	-	-	-	-	-	-	-	-	-
Other (income) expense, net	(134)	(159)	(150)	(137)	(127)	(121)	10	(111)	(83)	(176)	(111)	(93)
Earnings before taxes	1,524	1,449	2,180	2,150	1,778	1,940	1,607	1,436	1,671	1,636	1,562	1,758
Taxes on earnings	596	372	536	371	453	294	305	211	235	261	244	323
Earnings from continuing operations	-	-	-	-	-	-	-	-	-	-	-	-
Earnings (loss) from discontinued operations, net of tax	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of discontinued operations, net of tax	-	-	-	-	-	-	-	-	-	-	-	-
Earnings from discontinued operations, net of tax	-	-	-	-	-	-	-	-	-	-	-	-
Earnings from discontinued operations, net of tax	-	-	-	-	-	-	-	-	-	-	-	-
Net Earnings	$ 928	$ 1,077	$ 1,644	$ 1,779	$ 1,325	$ 1,646	$ 1,302	$ 1,225	$ 1,436	$ 1,375	$ 1,318	$ 1,435
Basic Earnings Per Common Share --
Continuing operations	-	-	-	-	-	-	-	-	-	-	-	-
Discontinued operations (in dollars per share)	-	-	-	-	-	-	-	-	-	-	-	-
Basic Earnings Per Common Share (in dollars per share)	0.53	0.62	0.94	1.02	0.76	0.94	0.74	0.70	0.82	0.79	0.75	0.82
Diluted Earnings Per Common Share --
Continuing operations	-	-	-	-	-	-	-	-	-	-	-	-
Discontinued operations (in dollars per share)	-	-	-	-	-	-	-	-	-	-	-	-
Diluted Earnings Per Common Share (in dollars per share)	0.53	0.61	0.94	1.01	0.76	0.94	0.74	0.70	0.82	0.78	0.75	0.81
Cash Dividends Declared Per Common Share (in dollars per share)	-	-	-	-	-	-	-	-	-	-	-	-
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,740,420	1,742,480	1,742,142	1,743,437	1,739,206	1,739,466	1,743,040	1,740,203	1,738,700	1,740,359	1,741,738	1,752,968
Dilutive Common Stock Options (in shares)	2,561	4,593	7,219	7,398	8,014	8,131	8,113	9,449	9,589	9,889	9,977	10,685
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,742,981	1,747,073	1,749,361	1,750,835	1,747,220	1,747,597	1,751,153	1,749,652	1,748,289	1,750,248	1,751,715	1,763,653
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	11,873	9,900	1,443	1,442	1,431	6,905	8,855	6,892	7,334	5,474	7,332	5,445